Nitrous oxide and perioperative cardiac morbidity (ENIGMA-II) Trial: rationale and design.

MLA

Myles, Paul S., et al. “Nitrous Oxide and Perioperative Cardiac Morbidity (ENIGMA-II) Trial: Rationale and Design.” American Heart Journal, vol. 157, no. 3, Mar. 2009, p. 488. EBSCOhost, https://doi.org/10.1016/j.ahj.2008.11.015.

APA

Myles, P. S., Leslie, K., Peyton, P., Paech, M., Forbes, A., Chan, M. T. V., Sessler, D., Devereaux, P. J., Silbert, B. S., Jamrozik, K., Beattie, S., Badner, N., Tomlinson, J., & Wallace, S. (2009). Nitrous oxide and perioperative cardiac morbidity (ENIGMA-II) Trial: rationale and design. American Heart Journal, 157(3), 488. https://doi.org/10.1016/j.ahj.2008.11.015

Chicago

Myles, Paul S, Kate Leslie, Philip Peyton, Michael Paech, Andrew Forbes, Matthew T V Chan, Daniel Sessler, et al. 2009. “Nitrous Oxide and Perioperative Cardiac Morbidity (ENIGMA-II) Trial: Rationale and Design.” American Heart Journal 157 (3): 488. doi:10.1016/j.ahj.2008.11.015.